Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 GBX | -7.04% | -13.16% | -22.35% |
04-15 | Fusion Antibodies inks commercial contract for OptiPhage library | AN |
04-15 | Fusion Antibodies Secures Contract to Set Up OptiPhage Library | MT |
Sales 2024 * | 1.15M 1.44M 115M | Sales 2025 * | - | Capitalization | 3.39M 4.24M 339M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M -100M | Net income 2025 * | - | EV / Sales 2024 * | 2.94 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-
| Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.63% |
1 day | -7.04% | ||
1 week | -13.16% | ||
Current month | -12.00% | ||
1 month | -14.29% | ||
3 months | -24.14% | ||
6 months | -37.14% | ||
Current year | -22.35% |
Managers | Title | Age | Since |
---|---|---|---|
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 14/08/22 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23/08/23 |
Simon Douglas
CHM | Chairman | 65 | 31/12/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colin Walsh
BRD | Director/Board Member | 68 | 31/12/06 |
Simon Douglas
CHM | Chairman | 65 | 31/12/05 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/12/01 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 3.3 | -7.04% | 2 143 352 |
29/04/24 | 3.55 | -2.74% | 340,618 |
26/04/24 | 3.65 | -2.67% | 167,778 |
25/04/24 | 3.75 | 0.00% | 220,253 |
24/04/24 | 3.75 | -1.32% | 187,413 |
Delayed Quote London S.E., April 30, 2024 at 01:32 pm
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.35% | 4.25M | |
+1.77% | 42.86B | |
+12.24% | 42.74B | |
+43.34% | 41.36B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- FAB Stock